Drugs / zalfermin
zalfermin
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07087795 | Jul 2025 → Sep 2026 overdue | type 1 diabetes mellitus | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06188026 | Dec 2023 → Dec 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05917938 | Jul 2023 → Dec 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05766709 | Mar 2023 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05742919 | Feb → Jun 2023 | NAFLD1 | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05727644 | Feb → Nov 2023 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04722653 | Feb → Apr 2021 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03479892 | Mar 2018 → Jun 2019 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT03015207 | Jan → Oct 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06409130 | May 2024 → Nov 2025 | alcoholic liver disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT05016882 | Aug 2021 → Dec 2024 | metabolic dysfunction-associated steatohepatitis | Novo Nordisk A/S | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zalfermin | “This first-in-human study investigated the safety, pharmacokinetics, and pharmacodynamics of the long-acting fibroblast growth factor 21 (FGF21) analog zalfermin.” PMID 41351276 ↗ Dec 2025 |
| Known as | NN-9499 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314897 ↗ |
| Known as | NNC0194-0499 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07087795 ↗ |
| Known as | Zalfermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314897 ↗ |
| Known as | Zalfermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314897 ↗ |
| Modality | Protein / enzyme biologic | “long-acting fibroblast growth factor 21 (FGF21) analog” PMID 41351276 ↗ Dec 2025 |
| Route | Subcutaneous | “subcutaneous zalfermin” PMID 41351276 ↗ Dec 2025 |